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Background: Gambogic acid has a marked anti-tumor effect for gastric and colorectal cancers in vitro and in vivo.
However, recent investigations on gambogic acid have focused mainly on mono-drug therapy, and its potential
role in cancer therapy has not been comprehensively illustrated. This study aimed to assess the interaction between
gambogic acid and docetaxel on human gastrointestinal cancer cells and to investigate the mechanism of
gambogic acid plus docetaxel treatment-induced apoptotic cell death.
Methods: MTT assay was used to determine IC50 values in BGC-823, MKN-28, LOVO and SW-116 cells after
gambogic acid and docetaxel administration. Median effect analysis was applied for determination of synergism and
antagonism. Synergistic interaction between gambogic acid and docetaxel was evaluated using the combination
index (CI) method. Furthermore, cellular apoptosis was analyzed by Annexin-V and propidium iodide (PI) double
staining. Additionally, mRNA expression of drug-associated genes, i.e., β-tublin III and tau, and the apoptosis-related
gene survivin, were measured by quantitative reverse transcription polymerase chain reaction (qRT-PCR).
Results: Gambogic acid provided a synergistic effect on the cytotoxicity induced by docetaxel in all four cell lines.
The combined application of gambogic acid and docetaxel enhanced apoptosis in gastrointestinal cancer cells.
Moreover, gambogic acid markedly decreased the mRNA expression of docetaxel-related genes, including β-tubulin
III, tau and survivin, in BGC-823 cells.
Conclusions: Gambogic acid plus docetaxel produced a synergistic anti-tumor effect in gastrointestinal cancer cells,
suggesting that the drug combination may offer a novel treatment option for patients with gastric and colorectal
cancers.Background
Despite a decline in incidence, gastric cancer remains one
of the leading causes of cancer-related deaths worldwide
[1]. Colorectal cancer is the third most common cancer
worldwide, with an incidence of approximately one million
cases and 500,000 mortalities annually [2,3]. Despite recent
advances in chemotherapeutic treatment of gastric cancer,
no single agent or combination regimen has been accepted
as a standard therapy [4]. For colorectal cancer, capecitabine
monotherapy or combination chemotherapies such as FOL-
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in any medium, provided the original work isand FOLFIRI (infusional 5-fluorouracil/leucovorin with iri-
notecan) are considered standard regimens. However, the
positive response rate is still lower than 40% [5,6]. Hence,
better systemic therapies are needed to decrease side effects
and improve the clinical outcomes of patients with gastric
and colorectal cancer.
Docetaxel (Doc), a widely used taxane for the treatment
of a variety of cancers, shares a similar mechanism of action
with paclitaxel [7]. Emerging lines of evidence indicate that
Doc is quite active against several human malignancies, in-
cluding gastric cancer [8,9]. Nevertheless, a poor prognosis
has been observed after Doc monotherapy. A previous re-
port demonstrated that administration of 100 mg/m2 Doc
to patients with adenocarcinoma of the upper gastrointes-
tinal tract, previously untreated with cytotoxic chemother-
apy, yielded a 17% response rate and only 2.8 months ofn Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
properly cited.
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that Doc plus cisplatin induces an overall response rate of
37.2% in patients with advanced gastric cancer, [10] suggest-
ing that Doc-containing combination therapy might be use-
ful in the management of gastric cancer.
Our previous study demonstrated that gambogic acid
(GA), the primary active component of gamboge, reversed
Doc resistance in BGC-823/Doc gastric cancer cells [11].
Moreover, GA alone or in combination with Doc signifi-
cantly down-regulates the mRNA expression of survivin in
gastric cancer cells, [11] implying that GA may promote the
anti-tumor effect of Doc through promotion of apoptotic
cell death. However, the synergistic anti-tumor effect of GA
and Doc in gastrointestinal cancer cells has not yet been
clearly illustrated.
In the present study, two gastric cancer cell lines,
MKN-28 and BGC-823, and two colorectal cancer cell
lines, LOVO and SW-116, were used to examine the
effects of GA and Doc mono-therapy or combination
therapy. Our results indicated that administration of GA
plus Doc enhanced apoptotic cell death in gastrointes-
tinal cancer cells compared to a single drug application,
suggesting that this drug combination may provide a
novel and beneficial treatment option for patients with
gastric and colorectal cancers.Methods
Reagents
Gambogic acid (GA, molecular formula C38H44O8) was
provided by Jiangsu Kangyuan Pharmaceutical Co., Ltd.
(Jiangsu, China). Docetaxel (Doc) was obtained from
Jiangsu Hengrui Pharmaceutical Co., Ltd. (Jiangsu, China).
GA and Doc were prepared in complete culture medium
immediately prior to use. RPMI 1640 medium was pur-
chased from GIBCO BRL (Grand Island, NY, USA). Fetal
bovine serum was obtained from Lanzhou National
Hyclone Bio-engineering Co., Ltd. (Lanzhou, Gansu, China).
MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazo-
lium bromide) was purchased from Sigma Chemical Co.
(St. Louis, MO, USA). Dimethyl sulfoxide (DMSO) was pro-
vided by Shanghai Ling-feng Chemical Reagents Co.
(Shanghai, China). All other chemicals used in this study
were of the highest purity available.Cell culture
Human cancer cell lines, specifically the gastric cancer
cell lines MKN-28 and BGC-823 and the colorectal can-
cer cell lines LOVO and SW-116, were obtained from
Shanghai Institute of Cell Biology (Shanghai, China).
Cells were maintained in RPMI 1640 medium supple-
mented with 10% fetal bovine serum. Cultures were
incubated at 37°C in a humidified atmosphere of
5% CO2.Evaluation of cytotoxicity
Cytotoxicity was measured using a MTT assay. Briefly,
tumor cells in log-phase were trypsinized and seeded at
a density of 2 × 103 cells per well onto 96-well plates.
After 24 h, cells were treated with GA, Doc, or GA plus
Doc at different concentrations. MTT (1/10 volume) was
added to each well after 48-h drug treatments, and plates
were further incubated at 37°C for another 4 h.
Formazan crystals formed were dissolved in DMSO.
Absorbance (OD) was determined with a multiwell spec-
trophotometer (BioTek, Winooski, VT, USA) at 570 nm.
Absorbance values were expressed as percentages rela-
tive to untreated controls. The IC50 was defined as the
concentration required for 50% inhibition of cell growth.
Each condition was tested in quintuplicate, and at least
three independent experiments were performed. The in-
hibition rate was calculated according to the following
equation: Inhibition rate (IR) (%) = [(average OD value in
the control group - average OD value in the treatment
group) / average OD value in the control group] × 100%.
Determination of synergism and antagonism
Synergism or antagonism after drug treatments was
quantitated with the median-effect principle, using the
combination index (CI) method [12]. The CI is defined
by the following equation: CI = [(D)1 / (Dx)1] + [(D)2 /
(Dx)2] + [α(D)1(D)2 / (Dx)1(Dx)2], where (Dx)1 and (Dx)
2 are the concentrations for D1 (GA) and D2 (Doc) that
give x% inhibition, whereas (D)1 and (D)2 in the
numerators are the concentrations of the two drugs that
produce an identical level of effect in combination. The
parameter α= 0 when the drugs are mutually exclusive
(i.e., with similar modes of action), while α= 1 if they are
mutually non-exclusive (i.e., with independent modes of
action). CI values> 1 indicate antagonism, CI values< 1
indicate synergy, and CI values = 1 indicate additivity.
Each CI ratio represented here is the mean value derived
from at least three independent experiments.
Assessment of apoptotic and necrotic cell death
Apoptotic or necrotic cell death was evaluated using an
annexin V-fluorescein isothiocyanate (FITC) Apoptosis
Detection Kit (BioVision, Mountain View, CA, USA)
according to the manufacturer’s instructions. MNK-28
cells were treated with 0.25 μM GA and 0.625 μM Doc;
BGC-823 cells were treated with 2.5 μM GA and
6.25 μM Doc; LOVO and SW-116 cells were treated with
1 μM GA and 2.5 μM Doc. After 48 h of drug treatment,
cells were harvested and resuspended in 500 μL of bind-
ing buffer. Annexin V-FITC and propidium iodide (PI)
were then added. Percentages of apoptotic or necrotic
cells were analyzed with a FACScan flow cytometer (Bec-
ton Dickinson, Sunnyvale, CA, USA). The cells in the
annexin V+ and PI– fraction were identified as early
Figure 1 Cytotoxic effects of GA and Doc treatment in cancer cells. After 48 h incubation with GA, Doc or GA plus Doc at the indicated
concentrations, cytotoxicity was determined by the MTT assay. Inhibition rates (%) in BGC-823 (A), MKN-28 (B), LOVO (C) and SW-116 (D) cells
were calculated as described in Methods. *P< 0.05 compared with GA plus Doc.
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fraction represented late apoptotic cells or necrotic cells.Table 1 IC50 value (μM) of different cells after 48 h of GA
or Doc treatment
Cell line GA Doc
BGC-823 2.33 ± 0.05 4.93 ± 0.57
MKN-28 1.66 ± 0.11 8.63 ± 1.90
LOVO 1.21 ± 0.11 4.49 ± 0.74
SW-116 2.14 ± 0.33 1.77 ± 0.43Quantitative reverse transcription polymerase chain
reaction (qRT-PCR)
Total RNA was extracted from BGC-823 cells after 48 h
incubation with or without GA. cDNA was synthesized
using random primers and Primescript reverse tran-
scriptase (Takara; Shiga, Japan). qPCR reactions for indi-
cated genes were carried out using SYBR green qPCR kit
(Takara; Shiga, Japan) by a fluorescent temperature
cycler (Mx3000P Real Time PCR System; Stratagene;
Santa Clara, CA, USA). Sequences of primers (forward
and reverse, respectively) were as follows: β-tubulin III:
5’-AGCAAGAACAGCAGCTACTTCGT-3’ and 5’-GAT-




β-actin: 5’-GCGAGAAGATGACCCAGATC-3’ and 5’-GGATAGCAACGCCTGGATAG-3’. Cycling conditions
were as follows: denaturation (95°C for 10 sec), amplifi-
cation and quantitation repeated for 45 cycles (95°C for
5 s, 60°C for 20 s, with a single fluorescence measure-
ment); a melting curve program (95°C for 10 s, 55-95°C
with a heating rate of 0.1°C/s and continuous fluores-
cence measurement). Relative gene expression was
quantified according to the comparative Ct method
using β-actin as an internal standard and cells without
GA treatment as calibrators. Gene expression was
Figure 2 Synergistic effects of GA and Doc on gastrointestinal cancer cells. (A1-4): Dose–response curves for BGC-823 (A1), MKN-28 (A2),
LOVO (A3) and SW116 (A4) cells. (B1-4): CI values at different levels of growth inhibitory effect (the fraction of cells affected, Fa) for BGC-823 (B1),
MKN28 (B2), LOVO (B3) and SW116 (B4) cells.
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Table 2 Summary of CI values at 20%, 40%, 60% and
80% fraction affected
CI (means± SD)
Cell line 20% 40% 60% 80%
BGC-823 0.87 ± 0.31 0.64 ± 0.15 0.54 ± 0.09 0.50 ± 0.07
MKN-28 0.57 ± 0.14 0.59 ± 0.06 0.61 ± 0.03 0.65 ± 0.11
LOVO 1.11 ± 0.26 0.90 ± 0.23 0.80 ± 0.21 0.76 ± 0.18
SW-116 1.47 ± 0.34 0.97 ± 0.07 0.73 ± 0.08 0.56 ± 0.14
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tified by the 2-ΔΔCt method.
Statistical analysis
Data were analyzed by using SPSS 15.0 software and
were expressed as means ± SD. Statistical analysis was
performed using the Student’s t-test. Values of P< 0.05
were considered to be statistically significant.
Results
Cytotoxic effects of GA and Doc treatment on cancer cells
The cytotoxic effects of GA and Doc on cancer cells
were first evaluated by using the MTT assay. As
expected, GA or Doc alone dose-dependently increased
cytotoxicity in the gastric cancer cell lines MKN-28 and
BGC-823 and the colorectal cancer cell lines LOVO and
SW-116 (Figure 1). Combined application of GA and
Doc markedly enhanced the cytotoxic effects in each of
the cell lines as compared with single drug administra-
tion (P< 0.05). Table 1 shows the half-maximal inhibi-
tory concentration (IC50) values for four cancer cells
lines exposed to GA or Doc. It should be noted that theFigure 3 Induction of MKN-28 cell death by GA and Doc. After 48 h inc
Doc (0.625 μM) (d), morphological changes in MKN-28 cells were observed
controls (a). (e) Annexin-V and PI double staining for cells from panel d). Sa
labeled cells with green fluorescence were recognized as early apoptotic ce
were recognized as late apoptotic or necrotic cells.lowest IC50 for GA or Doc treatment was detected in
LOVO (1.21 ± 0.11 μM) and SW-116 (1.77 ± 0.43 μM)
cells, respectively. We then used fixed-ratio concentra-
tions including each drug IC50 dose for the remaining
experiments.Synergistic effects of GA and Doc on
gastrointestinal cancer cells
To investigate whether GA could enhance the anti-
tumor effects of Doc, which is widely used in cancer
chemotherapy, the effects of each drug (administered
alone or in combination) were examined. The concentra-
tion ratio for the combined application of GA and Doc
was set as 1: 2.5, which is approximately the same as the
ratio of the IC50 values for each drug. Figure 2 shows the
dose–response curves and CI values at different levels of
growth inhibition effect (fraction affected, Fa) when GA
and Doc were administrated alone or in combination to
gastrointestinal cancer cells. In the gastric cancer cell
lines MKN-28 and BGC-823 and the colorectal cancer
cell lines LOVO and SW-116, the combination treatment
provided an efficient anti-tumor response compared with
single drug application, as revealed by the dose–response
curves (Figure 2A1-4).
CI values at different levels of Fa demonstrated that
when Fa> 0.15 for BGC-823 cells, > 0.25 for LOVO
cells, and> 0.40 for SW-116 cells, the CI values were
< 1, and the combination treatment with GA and Doc
could induce a synergistic, anti-proliferative effect
(Figure 2B1-4). The CI value was< 1 across almost the
entire dose-inhibition range when GA was combined
with Doc in MKN-28 cells, indicating a moreubation with GA (0.25 μM) (b), Doc (0.625 μM) (c) or GA (0.25 μM) plus
under light microscopy. Cells without any treatments were used as
mples were visualized under a fluorescent microscope. Annexin-V-
lls; annexin-V and PI double-labeled cells with orange fluorescence
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apy. These results are summarized in Table 2, which
indicates for each combination, a computer-calculated
CI for 20%, 40%, 60% and 80% cytotoxicity (Fa = 0.2, 0.4,
0.6, 0.8, respectively).
Combination treatment enhances apoptotic cell death
Based on the results obtained with the MTT assay and the
middle-effect principle, the lower concentration of GA plus
Doc could also induce remarkable growth suppression inFigure 4 Induction of apoptotic cell death by GA and Doc. After 48 h i
concentrations, cells were stained with annexin-V and PI as described in Me
(D) cells was analyzed by flow cytometry.gastrointestinal cancer cells. Hence, 0.25 μM GA and
0.625 μM Doc were administered for evaluation of apop-
totic cell death in MKN-28 cells. Forty-eight hours after
drug incubation, the morphological alterations of MKN-28
cells were observed using light microscopy. As shown by
Figure 3, increased cell loss was found after GA (0.25 μM)
plus Doc (0.625 μM) treatment. Similar with the results
obtained from MKN-28 cells, Annexin-V and PI double
staining of the other three cell lines all revealed that the
combination treatment induced apoptotic cell death (datancubation with GA, Doc or GA plus Doc at the indicated
thods. Apoptosis of BGC-823 (A), MKN-28 (B), LOVO (C) and SW-116
Figure 5 GA down-regulates the expression of genes involved
in Doc sensitivity. The mRNA expression of genes involved in Doc
sensitivity, including β-tubulin III, tau and survivin, in BGC-823 cells
was determined by qRT-PCR after 48 h of GA (0.25 μM) treatment.
The mRNA expression of target genes was normalized to a control.
*P< 0.01 compared with control. Data were quantified from three
independent experiments.
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SW-116 cells after combination treatment was further
determined by flow cytometry. Consistent with previous
observations, the proportion of apoptotic cells (annexin V+
PI+/−) was markedly increased by application of GA plus
Doc in all four cell lines as compared with GA or Doc treat-
ment alone (Figure 4). These results indicate that the com-
bination treatment enhanced apoptotic cell death in
gastrointestinal cancer cells.
GA downregulates the expression of genes involved in
docetaxel sensitivity
Accumulating evidence indicates that various cellular
proteins that are associated with microtubules can deter-
mine the sensitivity of cancer cells to microtubule-
targeting agents and play a role in tumor cell resistance
to these agents [13]. To explore the potential mechanism
by which GA plus Doc induces apoptotic cell death, the
expression of genes involved in Doc sensitivity that regu-
late microtubules, such as class III β-tubulin (β-tubulin
III) and tau, were evaluated by qRT-PCR. It should be
noted that 48 h of GA (0.25 μM) incubation markedly
down-regulated the expression of β-tubulin III and tau
(Figure 5). Moreover, the expression of survivin, which is
recognized as an apoptosis inhibitor, [14] was also sup-
pressed by GA administration (Figure 5). These results
imply that β-tubulin III, tau and survivin might be
involved in the GA-mediated anti-tumor effect.
Discussion
Gastrointestinal cancer is the most commonly diagnosed
cancer worldwide, exhibiting a high annual mortality [1-
3]. Chemotherapy has been recognized as the treatment
of choice for patients with gastric or colorectal cancer,
either alone or in combination with surgery with or
without radiotherapy [15,16]. Various chemotherapeutic
agents have been used for clinical treatment of patients,
including mitomycin C, cisplatin, doxorubicin, 5-fluor-
ouracil (5-FU), paclitaxel and Doc [17]. It has been
reported that the response rates range from 10% to 30%
for single-agent therapy and 30% to 60% for combination
therapy [17]. However, the overall outcome remains poor
due to local or distant recurrences, drug resistance or
side effects derived from the various drugs. Accumulat-
ing evidence suggests that certain natural phytochemical
compounds used in conjunction with chemotherapeutic
agents could enhance therapeutic efficacy by sensitizing
cells to treatment [18].
Doc, which is widely used for the treatment of several
human malignancies, has been reported to be active against
gastric cancer [8,9]. However, administration of Doc alone
often leads to undesirable side effects and drug resistance
[9,16]. The development of new taxane anticancer agents
with fewer side effects, superior pharmacological propertiesand improved activity against drug-resistant human cancers
seems to be a critical need for treatment of gastric cancer
[19]. Moreover, Doc-containing chemotherapy has gradually
developed with the aim of improving overall response rate
and survival [10].
GA, the primary active component of gamboge, has
been reported to induce apoptotic cell death of human
gastric cancer SGC-7901 and BGC-823 cells [20,21].
Treatment of Doc resistant BGC-823/Doc cells with GA
led to a dramatic increase in Doc-induced cytotoxicity.
Cell cycle analysis further indicated that GA treatment
potentiated Doc-induced G2/M cell cycle arrest. More-
over, GA singly or in combination with Doc significantly
downregulated the mRNA expression of survivin [11]. In
addition, combined treatment of GA and 5-FU caused
significant growth inhibition of BGC-823 human tumor
xenografts in vivo [22] Our previous study demonstrated
that GA reversed Doc resistance in BGC-823/Doc gastric
cancer cells [11]. In the present study, the combined ap-
plication of GA and Doc exhibited synergistic and effi-
cient anti-tumor effects in the human gastric cancer cell
lines MKN-28 and BGC-823, and colorectal cancer cell
lines LOVO and SW-116 (Figures 1 and 2), suggesting
that GA may enhance the anti-cancer effects of Doc in
both gastric and colorectal cancers. In addition, combin-
ation therapy suppressed the proliferation of cancer cells
in a dose-dependent manner (Figure 1). Furthermore,
the colorectal cancer cell line LOVO exhibited the lowest
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differentiated human gastric cancer cell MKN-28. With
regard to Doc treatment, SW-116 cells were the most
sensitive cell line followed by BGC-823 cells. However,
combined administration of GA and Doc provided a syn-
ergistic effect on growth suppression of MKN-28 cells.
Based on these observations, we hypothesize that growth
of highly differentiated tumor cells, such as MKN-28
cells, could be synergistically suppressed by GA and Doc
treatment. These observations are in accordance with
previous reports showing that the combined application
of 5-FU and GA had a stronger anti-gastric cancer effect
in BGC-823 cells than that of 5-FU or GA alone [22].
Survivin, a novel inhibitor of apoptosis (IAP), has been
reported to be associated with apoptosis, proliferation
and angiogenesis during human colorectal tumorigenesis
[23]. Moreover, survivin is also involved in tumor cell re-
sistance to certain anti-cancer agents [24]. Our previous
study demonstrated that GA reversed Doc resistance in
BGC-823/Doc gastric cancer cells by down-regulating
the expression of survivin,[11] implying that GA may
promote the anti-tumor effect of Doc through mediation
of apoptotic cell death. Here, we found that combination
therapy significantly enhanced cell apoptosis (Figures 3
and 4). In addition, GA reduced the mRNA expression
of survivin, suggesting that apoptosis might be involved
in the GA-mediated anti-tumor effect.
Microtubule-associated proteins, such as β-tubulin III
and tau, are known as essential predictive markers for
the sensitivity of taxane-based chemotherapy in several
human cancers [25,26]. Reduced expression of micro-
tubule-associated proteins is linked to better outcomes
for taxane therapy. Doc binds to β-tubulin, which is one
of the major components of microtubules, and exerts its
growth-inhibitory effects through G2/M cell cycle arrest.
This then induces mitochondrial dysfunction and cell
apoptosis. In the present study, GA treatment markedly
decreased the mRNA expression of β-tubulin III and tau,
suggesting these two genes were also involved in the
GA-induced anti-tumor effect.
In summary, our present study demonstrates that GA
and Doc combination treatment induced a synergistic,
anti-tumor effect in gastric and colorectal cancer cells.
Future studies will be focused on exploring the mechan-
ism of the interaction of GA and Doc in gastrointestinal
cancer cells and investigating the combination therapy
in vivo using animal models.
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